PATENT ATTORNEY DOCKET: 62611.000234

## IN THE ENITED STATES PATENT AND TRADEMARK OFFICE

Application Number

10/672,059

Confirmation No.:

4726

**Applicant** 

Linda ARTERBURN et al.

Filed

: September 29, 2003

Title

PROPHYLACTIC DHA THERAPY FOR PATIENTS WITH

SUBCLINICAL INFLAMMATION INCLUDING DIABETIC AND

PREDIABETIC PATIENTS

TC/Art Unit

1614

Examiner:

Unassigned

Docket No.

62611.000234

Customer No.

21967

## **Mail Stop Amendment**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants are submitting herewith copies of the references listed on the attached Form PTO-SB/08A (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Additionally, several of the attached documents were cited by the European Patent Office in the International Search Report dated April 26, 2004 of the corresponding application and relevance as asserted by the Searching Authority is indicated on the enclosed copy of the Search Report.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(e), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action, and within three months of the date of the corresponding Search Report.. Therefore, it is respectfully submitted that no fee is

required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

**HUNTON & WILLIAMS LLP** 

Dated: May 19, 2004

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

JTP/sdw

By:

Jeffrey T/Perez

Registration No. 52,110

PTO/SB/08A (10/01) (modified) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for form 1449A/PTO MAY 1 9 2004 **Application Number** 10/672,059 INFORMATION BUSCLOSURE **Filing Date** September 29, 2003 **First Named Inventor** Linda ARTERBURN et al. STATEMENT BY APPLICANT **Art Unit** 1614 (use as many sheets as necessary) **Examiner Name Unassigned** Sheet 1 of 4 **Attorney Docket Number** 62611.000234 **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, DOCUMENT NUMBER \*Examiner Cite Where Relevant Passages or **Publication Date** Name of Patentee or Initials No. Number - Kind Code (if known) MM-DD-YYYY Applicant of Cited Document Relevant Figures Appear US 5508310 Rhodes 04-16-1996 1. 2. US 5720304 02-24-1998 **Omura** US 20020055538 3. 05-09-2002 Serhan et al. FOREIGN PATENT DOCUMENTS **FOREIGN PATENT** Pages, Columns, DOCUMENT Lines, Where Name of Patentee or Relevant Passages or **TRANSLATION** Number - Kind Country \*Examiner Cite **Publication Date Applicant of Cited** Relevant Figures Code: Code (if known) Initial No. MM-DD-YYYY Document Appear YES NO EP 0675103 A3 10-04-1995 Horrobin et al. 4. NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the **TRANSLATION** \*Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials No. number(s), publisher, city and/or country where published YES NO FREEMAN et al., "C-Reaction Protein Is an Independent Predictor of Risk for the 5. Development of Diabetes in the West of Scotland Coronary Prevention Study," Diabetes, Vol. 51, May 2002, pp. 1596-1600 Diabetes In Control.com, "C-Reactive Protein Predicts Diabetes Risk in Middle-Age Men," 6. Item #5, 2 pages American Family Physician, November 15, 1999, Tips from other Journals, "Low- vs. High-7. Dose Aspirin After Carotid Endarterectomy," 2 pages

## **EXAMINER SIGNATURE**

pp. 643-654

8.

**DATE CONSIDERED** 

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SERHAN et al., "Anti-Microinflammatory Lipid Signals Generated From Dietary N-3 Fatty

Acids Via Cyclooxygenase-2 and Transcellular Processing: A Novel Mechanism For NSAID

And N-3 PUFA Therapeutic Actions," Journal of Physiology and Pharmacology, 2000, 51, 4,

Substitute for form 1449A/PTO						Ap	plication Number	10/672,059		
INIC	<b>-</b>	<u>نا</u> ب	AATI/	~N	NOOL OOLIDE	Fil	ing Date	September 29, 2003		-
					DISCLOSURE	Fir	rst Named Inventor	Linda ARTERBURN et a	ıl.	
31/	STATEMENT BY APPLICANT						t Unit	1614		
(use as many sheets as necessary)						Ex	aminer Name	Unassigned		
Sheet		2		of	4	Att	torney Docket Number	62611.000234		
	NON-PATENT LITERATURE DOCUMENTS									
*Examiner	Cite		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue							ATION
Initials	No.	-			number(s), publishe	ner, city	ty and/or country where publishe	ed	YES	NO
	9.		SERHA Actions Antiinfla							
		4	7/7/03, {http://www.jem.org/cgi/content/full/192/8/1197}, pp. 1-14							
	10.		BLANCO et al., "Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes," J. Rheumatol, 1999 Jun, 26 (6): 1366-73, Pub Med Abstract printed 7/7/03							
	11.		SERHAN et al., "Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals," J. Exp. Med. 2002 Oct.;196(8): 1025-37, Pub Med Abstract printed 7/7/03							
	12.		SVANEBORG et al., "The acute and short-time effect of supplementation with the combination of n-3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids," Thromb Res. 2002 Feb15;1054(4):311-6, Pub Med Abstract printed 7/7/03							
	13.		PATRIGNANI et al., "COX-2 is is not involved in thromboxane biosynthesis by activated human platelets," J. Physiol Pharmacol. 1999 Dec;50(4):661-7, Pub Med Abstract printed 7/7/03							
	14.		ANIL et al., "Effect of n-3 fatty acids on VLDL production by hepatocytes is mediated through prostaglandins," Biochem Mol. Biol. Int. 1997 Dec.;43(5):1071-80, Pub Med Abstract printed 7/7/03							
	15.		HINZ et al., "Salicylate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E(2) synthesis in murine macrophages," Biochem. Biophys. Res. Commun. 2000 Jul. 21;274(1):197-202, Pub Med Abstract printed 7/7/03							
	16.		HAWKEY, "COX-1 and COX-2 inhibitors," Best Pract. Res. Clin. Gastroenterol. 2001 Oct; 15(5):801-20, Pub Med Abstract printed 7/7/03							
	17.		PRADHAN et al., "Can serum markers predict the development of type 2 diabetes mellitus?," MD Digests, printed 8/21/02, 1 page, {http://www.healthstream.com/mddigestsmain.cfm?MDDigestID=1190}							
	18.		TEMELKOVA-KURKTSCHIEV et al., "Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance," Diabetologia 2002 Jan.;45(1):151, Pub Med Abstract printed 8/22/02							
EXAMI	VER	SIC	GNATURE	Ē		!	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line throughtain if not in conformance and not considered. Include copy of this form with next communication to applicant.										ough

Substitute for form 1449A/PTO **Application Number** 10/672,059 **Filing Date September 29, 2003** INFORMATION DISCLOSURE **First Named Inventor** Linda ARTERBURN et al. STATEMENT BY APPLICANT **Art Unit** 1614 (use as many sheets as necessary) **Examiner Name** Unassigned 3 Sheet of 4 **Attorney Docket Number** 62611.000234 NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the **TRANSLATION** \*Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials No. number(s), publisher, city and/or country where published YES NO VISSER et al., "Elevated C-Reaction Protein Levels in Overweight and Obese Adults," JAMA, 19. Vol. 282, No. 22, December 8, 1999, Abstract printed 8/21/02 {http://jama.amaassn.org/issues/v282n22/abs/joc91041.html} BERMUDEZ et al., "C-Reactive protein (CRP), statins, and the primary prevention of 20. atherosclerotic cardiovascular disease," Medscape from WebMD, {http://www.medscape.com/viewarticle/433236}, printed 9/18/03, 2 pages HART et al., "Aspirin dosage and thromboxane synthesis in patients with vascular disease," 21. Pharmacotherapy 23(5):579-584, 2003, Medscape Abstract, {http://www.medscape.com/viewarticle/455732}, 9 pages MADSEN et al., "C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery 22. disease," The American Journal of Cardiology, Vol. 88, Issue 10, 15 November 2001, pages 1139-1142, Science @ Direct Abstract, 1 page JEYARAJAH et al., Docosahexaenoic acid, a component of fish oil, inhibits nitric oxide 23. production in vitro," J. Surg. Res. 1999 May 15;83(2):147-50, Pub Med Abstract printed 9/17/03, 1 page MIYAZAKI et al., "Dietary docosahexaenoic acid ameliorates, but rapeseed oil and safflower 24. oil accelerate renal injury in stroke-prone spontaneously hypertensive rats as compared with soybean oil, which is associated with expression for renal transforming growth factor-beta, fibronectin and renin," Biochim. Biophys. Acta. 2000 Jan. 3;1483(1):101-10, Pub Med Abstract printed 9/17/03, 1 page YANO et al., "Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell 25. apoptosis induced by tumor necrosis factor," J. Nutr. 2000 May; 130(5):1095-101, Pub Med Abstract printed 9/17/03, 1 page 26. TEMELKOVA-KURKTSCHIEV et al., "Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes," Metabolism 2002 Jun; 51(6):743-9, Pub Med Abstract printed 8/22/02, 2 pages GALLOWAY et al., "Insulin-induced hypoglycemia induces a rise in C-reactive protein," 27. Diabetes Care, 2000 Jun;23(6):861-2, Pub Med Abstract printed 8/22/02, 3 pages 28. HANKEY et al., "Antiplatelet drugs," eMJA Abstract, MJA 2003; 178(11): 568-574, 13 pages **EXAMINER SIGNATURE** DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO **Application Number** 10/672,059 **Filing Date September 29, 2003** INFORMATION DISCLOSURE **First Named Inventor** Linda ARTERBURN et al. STATEMENT BY APPLICANT **Art Unit** 1614 (use as many sheets as necessary) **Examiner Name** Unassigned **Sheet** 4 4 of **Attorney Docket Number** 62611.000234 NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the TRANSLATION \*Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials No. number(s), publisher, city and/or country where published YES NO OFFERMANNS, "Antiplatelet Drugs," Molecular Pharmacology, 3 pages 29. SARGENT et al., "Recent developments in the essential fatty acid nutrition of fish," 30. Aquaculture 177 (1999) 191-199 JAMES et al., "Dietary polyunsaturated fatty acids and inflammatory mediator production," 31. Am. J. Clin. Nutr., 2000 Jan;71(1 Suppl):343S-8S, Pub Med Abstract printed 9/17/03, 1 page WATANABE et al., "Dietary docosahexaenoic acid butnot eicosapentaenoic acid suppresses 32. lipopolysaccharide-induced interleukin-1 beta mRNA induction in mouse spleen leukocytes," Prostaglandins Leukot. Essent. Fatty Acids., 2000 Mar.;62(3):147-52, Pub Med Abstract printed 9/17/03, 1 page ARTS et al., "Essential fatty acids" in aquatic ecosystems: a crucial link between diet human health and evolution," Can. J. Fish. Aquat. Sci. 58: 122-137 (2001) Clinical Insights Fax Program, Issue No. 29 (October 2, 2000), National Diabetes Education 34. Initiative For Healthcare Professionals, printed 8/21/02, {http://www.ndei.org/content/ndeipubs/clinical\_insights/fax100200.asp} CRP, Inflammation, and Subclinical Atherosclerosis," Medscape from WebMD, printed 35. 9/18/03, {http://www.medscape.com/viewarticle/433236\_2}, 1 page International Search Report dated April 26, 2004 for Application No. PCT/US03/30484 36. GRIEGER, "Diabetes and cardiovascular disease," printed from 37. {http://www.heartinfo.org/search/print.asp?id}, printed 8/21/02, 3 pages **EXAMINER SIGNATURE** DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.